Aurigene Pharmaceutical opens biologics facility in Hyderabad, India

Aurigene Pharmaceutical Services, a Dr Reddy’s Laboratories unit, has officially opened a new biologics facility at Genome Valley in the Indian city of Hyderabad.

The 70,000ft² facility is equipped to provide process and analytical development, as well as small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early-phase clinical trials.

The process and analytical development laboratories at the facility are already operational and the manufacturing capacity is expected to be commissioned later in 2024.

The facility features robust equipment and control systems and is supported by a skilled workforce to ensure a smooth transition to large-scale commercial current good manufacturing practice operations.

The new facility complements Aurigene’s existing discovery capabilities and infrastructure, which focus on a range of recombinant proteins. These proteins include monoclonal antibodies, bi and multi-specifics, immune-fusion molecules, antibody-drug conjugates and other complex proteins.

With the opening of the Hyderabad facility, Aurigene is equipped to offer comprehensive end-to-end services, from discovery through to large-scale commercial manufacturing, across three closely situated campuses.

The launch of the facility is part of Aurigene’s strategic initiatives to support growth in both the small molecule and biologics sectors.

June 5, 2024